WO1997020823A3 - 2-amino quinazoline derivatives as npy receptor antagonists - Google Patents

2-amino quinazoline derivatives as npy receptor antagonists Download PDF

Info

Publication number
WO1997020823A3
WO1997020823A3 PCT/EP1996/005067 EP9605067W WO9720823A3 WO 1997020823 A3 WO1997020823 A3 WO 1997020823A3 EP 9605067 W EP9605067 W EP 9605067W WO 9720823 A3 WO9720823 A3 WO 9720823A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
npy receptor
quinazoline derivatives
amino quinazoline
formula
Prior art date
Application number
PCT/EP1996/005067
Other languages
French (fr)
Other versions
WO1997020823A2 (en
Inventor
Heinrich Rueeger
Tibur Schmidlin
Pascal Rigollier
Yasuchika Yamaguchi
Marina Tintelnot-Blomley
Walter Schilling
Leoluca Criscione
Robert Mah
Original Assignee
Ciba Geigy Ag
Heinrich Rueeger
Tibur Schmidlin
Pascal Rigollier
Yasuchika Yamaguchi
Tintelnot Blomley Marina
Walter Schilling
Leoluca Criscione
Robert Mah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Heinrich Rueeger, Tibur Schmidlin, Pascal Rigollier, Yasuchika Yamaguchi, Tintelnot Blomley Marina, Walter Schilling, Leoluca Criscione, Robert Mah filed Critical Ciba Geigy Ag
Priority to AU76929/96A priority Critical patent/AU7692996A/en
Publication of WO1997020823A2 publication Critical patent/WO1997020823A2/en
Publication of WO1997020823A3 publication Critical patent/WO1997020823A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Abstract

The invention relates to a compound of formula (I) in which the variables are as defined and or a salt or a tautomer thereof; and relates to a method of treatment of disorders or diseases associated with NPY receptor subtype Y5, to pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and to the manufacture of the compounds of formula (I) or a salt thereof.
PCT/EP1996/005067 1995-12-01 1996-11-18 2-amino quinazoline derivatives as npy receptor antagonists WO1997020823A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76929/96A AU7692996A (en) 1995-12-01 1996-11-18 Receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56637895A 1995-12-01 1995-12-01
US08/566,378 1995-12-01

Publications (2)

Publication Number Publication Date
WO1997020823A2 WO1997020823A2 (en) 1997-06-12
WO1997020823A3 true WO1997020823A3 (en) 1997-07-17

Family

ID=24262639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005067 WO1997020823A2 (en) 1995-12-01 1996-11-18 2-amino quinazoline derivatives as npy receptor antagonists

Country Status (3)

Country Link
AU (1) AU7692996A (en)
WO (1) WO1997020823A2 (en)
ZA (1) ZA9610020B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299066B2 (en) 2008-04-21 2012-10-30 Shionogi & Co., Ltd. Compounds having NPY Y5 receptor antagonistic activity

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040356A1 (en) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
GB9709815D0 (en) * 1997-05-14 1997-07-09 Merck Sharp & Dohme Therapeutic method
KR20010020610A (en) * 1997-07-03 2001-03-15 해피 페너 ; 해리 에이치. 페너 2세 Certain diarylimidazole derivatives; a new class of npy specific ligands
ATE345330T1 (en) * 1997-08-25 2006-12-15 Bayer Corp HETEROCYCLIC KETONES AS NPY Y5 ANTAGONISTS
AU1262199A (en) * 1997-11-28 1999-06-16 Banyu Pharmaceutical Co., Ltd. Antihyperlipemic agents
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
RU2219167C2 (en) * 1998-04-29 2003-12-20 Орто-Макнейл Фармасьютикал, Инк. N-substituted aminotetralines as ligands for receptor of y5 of neuropeptide y useful in treatment of obesity and other disorders
CA2350714A1 (en) * 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
AU3840000A (en) 1999-04-20 2000-11-02 Meiji Seika Kaisha Ltd. Tricyclic compounds
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
DE60034783T2 (en) * 1999-04-22 2008-01-31 H. Lundbeck A/S, Valby SELECTIVE NPY (Y5) ANTAGONISTS
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
MXPA01011321A (en) * 1999-05-05 2003-08-01 Johnson & Johnson 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS.
US6841552B1 (en) 1999-05-05 2005-01-11 Ortho-Mcneil Pharmaceutical, Inc. 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
WO2001028987A1 (en) 1999-10-15 2001-04-26 Du Pont Pharmaceuticals Company Benzylcycloalkyl amines as modulators of chemokine receptor activity
US6291499B1 (en) * 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
SI2014285T1 (en) * 1999-11-26 2010-08-31 Shionogi & Co NPYY5 antagonists
MXPA03000308A (en) 2000-07-13 2003-06-06 Lilly Co Eli Beta3 adrenergic agonists.
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
ES2193875B2 (en) 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1398032A1 (en) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
JP2006514646A (en) * 2002-12-13 2006-05-11 スミスクライン ビーチャム コーポレーション Cyclohexyl compounds as CCR5 antagonists
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100475793C (en) * 2003-03-31 2009-04-08 大正制药株式会社 Quinazoline derivatives and use for preparing medicine
JP2004315511A (en) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Mch receptor antagonist
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
ES2222833B1 (en) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 1,4-DISPOSED PIPERIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
EP1669350B1 (en) 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
WO2005040157A2 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2558915A1 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
JP2008505910A (en) * 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Pyrimidine derivatives useful as inhibitors of PKC-theta
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR101397913B1 (en) 2005-05-30 2014-05-26 엠에스디 가부시키가이샤 Novel piperidine derivative
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AU2006259525B2 (en) 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compounds
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
RU2008116844A (en) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Acylated Spiropiperidine Derivatives as Modulators of the Melanocortin-4 Receptor
BRPI0617621A2 (en) 2005-10-21 2011-08-02 Novartis Ag combination of organic compounds
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk Novel benzoxathiin derivative
JP4371164B2 (en) 2005-11-10 2009-11-25 萬有製薬株式会社 Aza-substituted spiro derivatives
CA2650683A1 (en) 2006-04-28 2007-11-08 Shionogi & Co., Ltd. Amine derivative having npy y5 receptor antagonist activity
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
SA08290668B1 (en) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
PE20091309A1 (en) * 2007-12-21 2009-09-30 Astrazeneca Ab CYCLOHEXYL DERIVATIVES AS ACETYL COENZYME CARBOXYLASE INHIBITORS
JPWO2009110510A1 (en) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 Alkylaminopyridine derivatives
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EA019289B1 (en) 2008-04-21 2014-02-28 Тайджен Байотекнолоджи Ко., Лтд. Aminopiridin, aminopirimidin and amino-1,3,5-triazine derivatives
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CN102264228A (en) 2008-10-22 2011-11-30 默沙东公司 Novel cyclic benzimidazole derivatives useful for anti-diabetic agents
KR101320245B1 (en) 2008-10-30 2013-10-30 머크 샤프 앤드 돔 코포레이션 Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
JP5685181B2 (en) * 2009-03-05 2015-03-18 塩野義製薬株式会社 Cyclohexane derivative having NPYY5 receptor antagonistic action
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
BR112012008330B1 (en) * 2009-09-03 2022-03-22 Bristol-Myers Squibb Company Quinazoline compounds, their pharmaceutical compositions and their uses
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP2013520502A (en) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
JP5688745B2 (en) 2010-03-10 2015-03-25 プロビオドルグ エージー Heterocyclic inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP5812500B2 (en) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション Novel β3 adrenergic receptor agonist
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2901114T3 (en) 2014-08-29 2022-03-21 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
MX2021005904A (en) 2018-11-20 2021-09-08 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE.
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202045476A (en) 2019-02-13 2020-12-16 美商默沙東藥廠 5-alkyl pyrrolidine orexin receptor agonists
JP2022540253A (en) 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ， インコーポレイテッド Formulations of T-type calcium channel modulators and methods of use thereof
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists
CN114315802B (en) * 2021-12-14 2023-06-16 西安医学院 Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application
WO2023121429A1 (en) * 2021-12-24 2023-06-29 아주대학교산학협력단 Novel compound for improving sleep or use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0448765A1 (en) * 1990-03-30 1991-10-02 HEUMANN PHARMA GMBH & CO Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity
WO1992007844A1 (en) * 1990-11-06 1992-05-14 Pfizer Inc. Quinazolines derivatives for enhancing antitumor activity
EP0614911A1 (en) * 1993-02-15 1994-09-14 Sanofi Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them
WO1996012489A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0448765A1 (en) * 1990-03-30 1991-10-02 HEUMANN PHARMA GMBH & CO Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity
WO1992007844A1 (en) * 1990-11-06 1992-05-14 Pfizer Inc. Quinazolines derivatives for enhancing antitumor activity
EP0614911A1 (en) * 1993-02-15 1994-09-14 Sanofi Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them
WO1996012489A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. GIARDINA ET. AL.: "Structure-Activity Relationships in Prazosin-Related Compounds. 2. Role of the Piperazine Ring on alpha-Blocking Activity.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 6, June 1993 (1993-06-01), WASHINGTON DC, US, pages 690 - 8, XP000652149 *
E. F. ELSLAGER ET. AL.: "Synthesis and Antimalarial Effects of N2-Aryl-N4-[(dialkylamino)alkyl]- and N4-Aryl-N2-[(dialkylamino)alkyl]- 2,4-quinazolinediamines.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, no. 2, February 1981 (1981-02-01), WASHINGTON DC, US, pages 127 - 40, XP000653661 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299066B2 (en) 2008-04-21 2012-10-30 Shionogi & Co., Ltd. Compounds having NPY Y5 receptor antagonistic activity

Also Published As

Publication number Publication date
AU7692996A (en) 1997-06-27
WO1997020823A2 (en) 1997-06-12
ZA9610020B (en) 1997-06-01

Similar Documents

Publication Publication Date Title
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
CA2216796A1 (en) Quinazoline derivatives
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2003048164A3 (en) Adenosine a2a receptor antagonists
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
WO1999054326A8 (en) Dihydropyrimidines
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
ZA913134B (en) Pyridazinone derivatives
ATE284861T1 (en) N-ARALKYLAMINOTETRALINES AS NEUROPEPTIDE Y-Y5 RECEPTOR LIGANDS
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
MXPA03010565A (en) Quinoline derivatives as ligands for the neuropeptide y receptor.
CA2468649A1 (en) Adenosine a2a receptor antagonists
MXPA04002825A (en) Quinoline derivatives as neuropeptide y antagonists.
CA2080705A1 (en) Substituted pyrimidines
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
MXPA04002338A (en) Carbazole derivatives and their use as npy5 receptor antagonists.
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
EP1551803B8 (en) Azabicyclo derivatives as muscarinic receptor antagonists
CA2386799A1 (en) Fused cycloheptane and fused azacycloheptane compounds and their as integrin receptor antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
BR9503572A (en) Compound pharmaceutical composition and method of treatment or prevention of a disease
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
AU2002347553A1 (en) Flavaxate derivatives as muscarinic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97520912

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA